Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 1:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–42 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: testosterone propionate Clear all
Recruiting Phase 4 Interventional

Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance

NCT06733350
View directory record Official record
Conditions
Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions
Biopsy of Prostate, Biospecimen Collection, Magnetic Resonance Imaging, Patient Observation, Questionnaire Administration, Therapeutic Testosterone
Procedure · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 18, 2026, 1:57 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer

NCT05081193
View directory record Official record
Conditions
Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Interventions
Testosterone Undecanoate, Enzalutamide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Baltimore, Maryland • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 18, 2026, 1:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Axiron® in Healthy Participants

NCT02004132
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Axiron
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Sep 18, 2026, 1:57 AM EDT
Completed Phase 4 Interventional

Xiaflex® Plus Testosterone Treatment Pilot Study Protocol

NCT03815331
View directory record Official record
Conditions
Peyronie's Disease (PD)
Interventions
Xiaflex®, Aveed
Drug
Lead sponsor
Men's Health Boston
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Sep 18, 2026, 1:57 AM EDT
Completed Phase 4 Interventional Results available

Patient Satisfaction After Switching to Oral Testosterone Undecanoate

NCT04983940
View directory record Official record
Conditions
Testosterone Deficiency
Interventions
Jatenzo
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Sep 18, 2026, 1:57 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

NCT00613002
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
testosterone gel, placebo gel
Drug
Lead sponsor
BioSante Pharmaceuticals
Industry
Eligibility
30 Years to 65 Years · Female only
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
60
States / cities
Birmingham, Alabama • Hoover, Alabama • Huntsville, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced Sep 18, 2026, 1:57 AM EDT
Completed Phase 1 Interventional

Testosterone in Treating Patients With Progressive Prostate Cancer That No Longer Responds to Hormone Therapy

NCT00006044
View directory record Official record
Conditions
Prostate Cancer
Interventions
therapeutic testosterone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Sep 18, 2026, 1:57 AM EDT
Completed Phase 2 Interventional Results available

COMbination of Bipolar Androgen Therapy and Nivolumab

NCT03554317
View directory record Official record
Conditions
Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer
Interventions
Testosterone cypionate, Nivolumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
San Francisco, California • Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Sep 18, 2026, 1:57 AM EDT
Completed Phase 1 Interventional Results available

Study of Testosterone and rHGH in FSHD

NCT03123913
View directory record Official record
Conditions
Facioscapulohumeral Muscular Dystrophy
Interventions
Testosterone Enanthate, Somatropin
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Sep 18, 2026, 1:57 AM EDT
Recruiting Phase 2 Interventional

Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

NCT06039371
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Scan, Carboplatin, Computed Tomography, Etoposide, Quality-of-Life Assessment, Questionnaire Administration, Testosterone Cypionate, Radioconjugate, Dual X-ray Absorptiometry, Gallium Ga 68-PSMA-617, Positron Emission Tomography, Single Photon Emission Computed Tomography
Procedure · Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 18, 2026, 1:57 AM EDT
Completed Phase 2 Interventional Results available

Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer

NCT03516812
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma
Interventions
Laboratory Biomarker Analysis, Olaparib, Quality-of-Life Assessment, Survey Administration, Testosterone Enanthate, Testosterone Cypionate
Other · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Sep 18, 2026, 1:57 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Testosterone Replacement Therapy in Chronic Spinal Cord Injury

NCT00266864
View directory record Official record
Conditions
Spinal Cord Injury, Hypogonadism
Interventions
Testosterone Transdermal System (Androderm 5 mg patch)
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 49 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
2
States / cities
West Orange, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2017 · Synced Sep 18, 2026, 1:57 AM EDT
Completed Phase 4 Interventional Results available

The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel

NCT01893281
View directory record Official record
Conditions
Hypogonadism
Interventions
Topical Testosterone Solution
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
21
States / cities
Encinitas, California • San Diego, California • Parker, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2014 · Synced Sep 18, 2026, 1:57 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Comparing Direct and Indirect Detection Methods of Multiple Routes of Testosterone Administration

NCT06393634
View directory record Official record
Conditions
Healthy
Interventions
Testosterone injection, Testosterone gel, Testosterone Oral
Drug
Lead sponsor
Sports Medicine Research and Testing Laboratory
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
South Jordan, Utah
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Sep 18, 2026, 1:57 AM EDT
Suspended Phase 1Phase 2 Interventional

Vaginal Testosterone Cream For Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer.

NCT01122342
View directory record Official record
Conditions
Vaginitis, Dyspareunia, Breast Neoplasms
Interventions
Testosterone propionate
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Pawtucket, Rhode Island • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 12, 2010 · Synced Sep 18, 2026, 1:57 AM EDT
Active, not recruiting Phase 1 Interventional

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

NCT06305598
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy, Bone Scan, Computed Tomography, Leuprolide Acetate, Magnetic Resonance Imaging, Survey Administration, Testosterone Cypionate
Procedure · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 18, 2026, 1:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Effect of Deodorant and Axillary Hair on Testosterone Absorption in Healthy Participants

NCT01725451
View directory record Official record
Conditions
Healthy Participants
Interventions
Testosterone, Deodorant Spray, Deodorant and Antiperspirant Combination Spray, Deodorant and Antiperspirant Combination Stick
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Daytona Beach, Florida • Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Sep 18, 2026, 1:57 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Effect of Sex Steroid Replacement Therapy in the Hypogonadism and Transgender Active-Duty Population

NCT06247267
View directory record Official record
Conditions
Hypogonadism, Gender Identity Dysphoria
Interventions
Fortesta, Estradiol
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Sep 18, 2026, 1:57 AM EDT